Ignyta INC (RXDX) Holder Cormorant Asset Management LLC Has Increased Its Holding

March 14, 2018 - By reb123z

Investors sentiment decreased to 2.28 in 2017 Q3. Its down 0.68, from 2.96 in 2017Q2. It turned negative, as 14 investors sold RXDX shares while 18 reduced holdings. 35 funds opened positions while 38 raised stakes. 44.98 million shares or 5.65% more from 42.58 million shares in 2017Q2 were reported. Panagora Asset Management accumulated 0.01% or 125,773 shares. The Ontario – Canada-based Bancorp Of Montreal Can has invested 0% in Ignyta, Inc. (NASDAQ:RXDX). Meeder Asset reported 186 shares stake. D E Shaw And Co has invested 0% in Ignyta, Inc. (NASDAQ:RXDX). Bogle Investment Management LP De holds 628,015 shares or 0.53% of its portfolio. Wells Fargo Co Mn accumulated 988,227 shares. Citadel Advsrs Limited Liability Co has invested 0% in Ignyta, Inc. (NASDAQ:RXDX). Parametric Portfolio Assoc Limited Company reported 0% of its portfolio in Ignyta, Inc. (NASDAQ:RXDX). Trexquant Investment Limited Partnership holds 0.04% of its portfolio in Ignyta, Inc. (NASDAQ:RXDX) for 12,345 shares. Lombard Odier Asset (Usa) holds 0.44% or 500,000 shares in its portfolio. Pacad Inv Ltd invested in 1,683 shares. Moreover, Aqr Capital Ltd Liability Corp has 0% invested in Ignyta, Inc. (NASDAQ:RXDX). Alliancebernstein LP owns 115,300 shares. 446,298 were reported by Axa. Great Point Lc has invested 2.98% in Ignyta, Inc. (NASDAQ:RXDX).

Cormorant Asset Management Llc increased its stake in Ignyta Inc (RXDX) by 133.33% based on its latest 2017Q3 regulatory filing with the SEC. Cormorant Asset Management Llc bought 2.00M shares as the company’s stock declined 28.13% while stock markets rallied. The hedge fund held 3.50 million shares of the health care company at the end of 2017Q3, valued at $43.23M, up from 1.50 million at the end of the previous reported quarter. Cormorant Asset Management Llc who had been investing in Ignyta Inc for a number of months, seems to be bullish on the $1.82 billion market cap company. It closed at $26.95 lastly. It is down 14.24% since March 14, 2017 and is uptrending. It has underperformed by 2.46% the S&P500.

Cormorant Asset Management Llc, which manages about $841.40 million and $566.36 million US Long portfolio, decreased its stake in Nevro Corp by 170,000 shares to 100,000 shares, valued at $9.09M in 2017Q3, according to the filing. It also reduced its holding in Aclaris Therapeutics Inc by 170,000 shares in the quarter, leaving it with 550,000 shares, and cut its stake in Bluebird Bio Inc (NASDAQ:BLUE).

More news for Ignyta, Inc. (NASDAQ:RXDX) were recently published by: Streetinsider.com, which released: “Form POS AM Ignyta, Inc.” on February 12, 2018. Fool.com‘s article titled: “Why Ignyta, Inc. Stock Is Soaring Today” and published on December 22, 2017 is yet another important article.

Ignyta, Inc. (NASDAQ:RXDX) Ratings Coverage

Among 10 analysts covering Ignyta (NASDAQ:RXDX), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Ignyta has $38 highest and $1500 lowest target. $24.13’s average target is -10.46% below currents $26.95 stock price. Ignyta had 20 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Ignyta, Inc. (NASDAQ:RXDX) has “Buy” rating given on Tuesday, November 21 by SunTrust. The company was initiated on Friday, October 23 by Jefferies. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report. The company was maintained on Monday, July 10 by Cantor Fitzgerald. The firm has “Buy” rating by Cantor Fitzgerald given on Sunday, June 4. The rating was initiated by JP Morgan with “Overweight” on Thursday, June 23. The rating was downgraded by Jefferies to “Hold” on Friday, December 22. The stock of Ignyta, Inc. (NASDAQ:RXDX) has “Buy” rating given on Tuesday, November 10 by Cantor Fitzgerald. The rating was maintained by JP Morgan on Thursday, October 12 with “Overweight”. The stock of Ignyta, Inc. (NASDAQ:RXDX) earned “Outperform” rating by Credit Suisse on Tuesday, March 15.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: